Standard Therapies For Pulmon... Health Article

References

[1] Romberg E.. Über sklerose der lungen arterie Dtsch Arch Klin Med 48 1891 197 206
[2] Dresdale D.T., Schultz M., Michtom R.J.. Primary pulmonary hypertension. I: clinical and hemodynamic study Am J Med 11 6 1951 686 705
[3] Rich S., Dantzker D.R., Ayres S.M.. Primary pulmonary hypertension: a national prospective study Ann Intern Med 107 2 1987 216 223
[4] Rubin L.J., Mendoza J., Hood M.. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial Ann Intern Med 112 7 1990 485 491
[5] Barst R.J., Rubin L.J., McGoon M.D.. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin Ann Intern Med 121 6 1994 409 415
[6] Barst R., Rubin L.J., Long W.A.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group N Engl J Med 334 5 1996 296 302
[7] Rich S., McLaughlin V.V.. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension J Am Coll Cardiol 34 4 1999 1184 1187
[8] Badesch D.B., Tapson V.F., McGoon M.D.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial Ann Intern Med 132 6 2000 425 434
[9] Hoeper M.M., Schwarze M., Ehlerding S.. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue N Engl J Med 342 25 2000 1866 1870
[10] Channick R.N., Simonneau G., Sitbon O.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 9288 2001 1119 1123
[11] Rubin L.J., Badesch D.B., Barst R.J.. Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 12 2002 896 903
[12] Simonneau G., Barst R.J., Galie N.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 6 2002 800 804
[13] Sitbon O., Humbert M., Nunes H.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 4 2002 780 788
[14] McLaughlin V.V., Shillington A., Rich S.. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 12 2002 1477 1482
[15] Ghofrani H.A., Wiedemann R., Rose F.. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension Ann Intern Med 136 7 2002 515 522
[16] Sitbon O., Gressin V., Speich R.. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension Am J Respir Crit Care Med 170 11 2004 1212 1217
[17] Mikhail G.W., Prasad S.K., Li W.. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects Eur Heart J 25 5 2004 431 436
[18] Wilkins M.R., Paul G.A., Strange J.W.. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study Am J Respir Crit Care Med 171 11 2005 1292 1297
[19] McLaughlin V.V., Sitbon O., Badesch D.B.. Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2 2005 244 249
[20] Galie N., Ghofrani H.A., Torbicki A.. Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 20 2005 2148 2157
[21] Barst R.J., Langleben D., Badesch D.. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol 47 10 2006 2049 2056
[22] Naeije R., Vachiery J.L.. Medical therapy of pulmonary hypertension: conventional therapies Clin Chest Med 22 3 2001 517 527
[23] Rich S., Seidlitz M., Dodin E.. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension Chest 114 3 1998 787 792
[24] Wagenvoort C.A.. Lung biopsy specimens in the evaluation of pulmonary vascular disease Chest 77 5 1980 614 625
[25] Bjornsson J., Edwards W.D.. Primary pulmonary hypertension: a histopathologic study of 80 cases Mayo Clin Proc 60 1 1985 16 25
[26] Pietra G.G., Edwards W.D., Kay J.M.. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry Circulation 80 5 1989 1198 1206
[27] Fuster V., Steele P.M., Edwards W.D.. Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 4 1984 580 587
[28] Kawut S.M., Horn E.M., Berekashvili K.K.. New predictors of outcome in idiopathic pulmonary arterial hypertension Am J Cardiol 95 2 2005 199 203
[29] Rich S., Kaufmann E., Levy P.S.. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 2 1992 76 81
[30] Johnson S.R., Granton J.T., Mehta S.. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension Chest 130 2 2006 545 552
[31] Sandoval J., Aguirre J.S., Pulido T.. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome Am J Respir Crit Care Med 164 9 2001 1682 1687
[32] Sitbon O., Humbert M., Jais X.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 23 2005 3105 3111
[33] Barst R.J., Maislin G., Fishman A.P.. Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 9 1999 1197 1208
[34] Rich S., Brundage B.H.. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy Circulation 76 1 1987 135 141
[35] Badesch D.B., Abman S.H., Ahearn G.S.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 1 Suppl 2004 35S 62S
[36] Galie N., Torbicki A., Barst R.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology Eur Heart J 25 24 2004 2243 2278
[37] British Cardiac Society Guidelines and Medical Practice Committee, Gibbs JS, Higenbottam TW. Recommendations on the management of pulmonary hypertension in clinical practice Heart 86 Suppl 1 2001 11 13
[38] Weissmann N., Hassell K.L., Badesch D.B.. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol 279 4 2000 L683 L690
[39] Nocturnal Oxygen Therapy Trial Group null. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group Ann Intern Med 93 3 1980 391 398
[40] Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party Lancet 1 8222 1981 681 686
[41] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report Global initiative for chronic obstructive pulmonary lung disease 2005 National Heart, Lung and Blood Institute Bethesda (MD)
[42] Owens G.R., Rogers R.M., Pennock B.E.. The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease N Engl J Med 310 19 1984 1218 1221
[43] Kelley M.A., Panettieri R.A., Krupinski A.V.. Resting single-breath diffusing capacity as a screening test for exercise-induced hypoxemia Am J Med 80 5 1986 807 812
[44] Bowyer J.J., Busst C.M., Denison D.M.. Effect of long term oxygen treatment at home in children with pulmonary vascular disease Br Heart J 55 4 1986 385 390
[45] Widlitz A., Barst R.J.. Pulmonary arterial hypertension in children Eur Respir J 21 1 2003 155 176
[46] Douglas N.J., White D.P., Pickett C.K.. Respiration during sleep in normal man Thorax 37 11 1982 840 844
[47] Koo K.W., Sax D.S., Snider G.L.. Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease Am J Med 58 5 1975 663 670
[48] Atwood C.W., McCrory D., Garcia J.G.. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines Chest 126 1 Suppl 2004 72S 77S
[49] Podszus T., Bauer W., Mayer J.. Sleep apnea and pulmonary hypertension Klin Wochenschr 64 3 1986 131 134
[50] Weitzenblum E., Krieger J., Apprill M.. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome Am Rev Respir Dis 138 2 1988 345 349
[51] Krieger J., Sforza E., Apprill M.. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients Chest 96 4 1989 729 737
[52] Apprill M., Weitzenblum E., Krieger J.. Frequency and mechanism of daytime pulmonary hypertension in patients with obstructive sleep apnoea syndrome Cor Vasa 33 1 1991 42 49
[53] Laks L., Lehrhaft B., Grunstein R.. Pulmonary hypertension in obstructive sleep apnoea Eur Respir J 8 4 1995 537 541
[54] Chaouat A., Weitzenblum E., Krieger J.. Pulmonary hemodynamics in the obstructive sleep apnea syndrome: results in 220 consecutive patients Chest 109 2 1996 380 386
[55] Sajkov D., Wang T., Saunders N.. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease Am J Respir Crit Care Med 159 5 Pt 1 1999 1518 1526
[56] Sanner B.M., Doberauer C., Konermann M.. Pulmonary hypertension in patients with obstructive sleep apnea syndrome Arch Intern Med 157 21 1997 2483 2487
[57] Niijima M., Kimura H., Edo H.. Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome Am J Respir Crit Care Med 159 6 1999 1766 1772
[58] Bady E., Achkar A., Pascal S.. Pulmonary arterial hypertension in patients with sleep apnoea syndrome Thorax 55 11 2000 934 939
[59] Alchanatis M., Tourkohoriti G., Kakouros S.. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics Respiration 68 6 2001 566 572
[60] Yamakawa H., Shiomi T., Sasanabe R.. Pulmonary hypertension in patients with severe obstructive sleep apnea Psychiatry Clin Neurosci 56 3 2002 311 312
[61] Abenhaim L., Moride Y., Brenot F.. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group N Engl J Med 335 9 1996 609 616
[62] Sajkov D., Wang T., Saunders N.A.. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea Am J Respir Crit Care Med 165 2 2002 152 158
[63] Arias M.A., Garcia-Rio F., Alonso-Fernandez A.. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure. A randomized, controlled cross-over study Eur Heart J 27 9 2006 1106 1113
[64] Kessler R., Chaouat A., Schinkewitch P.. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases Chest 120 2 2001 369 376
[65] Masa J.F., Celli B.R., Riesco J.A.. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation Chest 119 4 2001 1102 1107
[66] Sugerman H.J., Baron P.L., Fairman R.P.. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss Ann Surg 207 5 1988 604 613
[67] Pitt B., Zannad F., Remme W.J.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 10 1999 709 717
[68] Hunt S.A.. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 46 6 2005 e1 e82
[69] Quinn D.A., Du H.K., Thompson B.T.. Amiloride analogs inhibit chronic hypoxic pulmonary hypertension Am J Respir Crit Care Med 157 4 Pt 1 1998 1263 1268
[70] Krayenbuehl H.P., Turina J., Hess O.. Left ventricular function in chronic pulmonary hypertension Am J Cardiol 41 7 1978 1150 1158
[71] Dittrich H.C., Chow L.C., Nicod P.H.. Early improvement in left ventricular diastolic function after relief of chronic right ventricular pressure overload Circulation 80 4 1989 823 830
[72] Gan C.T., Lankhaar J.W., Marcus J.T.. Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension Am J Physiol Heart Circ Physiol 290 4 2006 H1528 H1533
[73] Akera T., Baskin S.I., Tobin T.. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K +)- activated ATPase Naunyn Schmiedebergs Arch Pharmacol 277 2 1973 151 162
[74] Mathur P.N., Powles P., Pugsley S.O.. Effect of digoxin on right ventricular function in severe chronic airflow obstruction: a controlled clinical trial Ann Intern Med 95 3 1981 283 288
[75] The Digitalis Investigation Group null. The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 8 1997 525 533
[76] Jelliffe R.W., Brooker G.. A nomogram for digoxin therapy Am J Med 57 1 1974 63 68
[77] Rathore S.S., Curtis J.P., Wang Y.. Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 7 2003 871 878
[78] Fogelman A.M., La Mont J.T., Finkelstein S.. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients Lancet 2 7727 1971 727 729
[79] Ingelfinger J.A., Goldman P.. The serum digitalis concentration: does it diagnose digitalis toxicity? N Engl J Med 294 16 1976 867 870
[80] Leor J., Goldbourt U., Rabinowitz B.. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. The SPRINT Study Group Cardiovasc Drugs Ther 9 5 1995 723 729
[81] Eichhorn E.J., Gheorghiade M.. Digoxin Prog Cardiovasc Dis 44 4 2002 251 266
[82] Hager W.D., Fenster P., Mayersohn M.. Digoxin-quinidine interaction pharmacokinetic evaluation N Engl J Med 300 22 1979 1238 1241
[83] Bizjak E.D., Mauro V.F.. Digoxin-macrolide drug interaction Ann Pharmacother 31 9 1997 1077 1079
[84] Juurlink D.N., Mamdani M., Kopp A.. Drug-drug interactions among elderly patients hospitalized for drug toxicity JAMA 289 13 2003 1652 1658
[85] Archer S.L., Djaballah K., Humbert M.. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension Am J Respir Crit Care Med 158 4 1998 1061 1067
[86] Lopes A.A., Maeda N.Y., Almeida A.. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension Angiology 44 9 1993 701 706
[87] Herve P., Launay J.M., Scrobohaci M.L.. Increased plasma serotonin in primary pulmonary hypertension Am J Med 99 3 1995 249 254
[88] Kereveur A., Callebert J., Humbert M.. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy Arterioscler Thromb Vasc Biol 20 10 2000 2233 2239
[89] Cacoub P., Karmochkine M., Dorent R.. Plasma levels of thrombomodulin in pulmonary hypertension Am J Med 101 2 1996 160 164
[90] Giaid A., Saleh D.. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 4 1995 214 221
[91] Collados M.T., Sandoval J., Lopez S.. Characterization of von Willebrand factor in primary pulmonary hypertension Heart Vessels 14 5 1999 246 252
[92] Hoeper M.M., Sosada M., Fabel H.. Plasma coagulation profiles in patients with severe primary pulmonary hypertension Eur Respir J 12 6 1998 1446 1449
[93] Wolf M., Boyer-Neumann C., Parent F.. Thrombotic risk factors in pulmonary hypertension Eur Respir J 15 2 2000 395 399
[94] Sakamaki F., Kyotani S., Nagaya N.. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy Circulation 102 22 2000 2720 2725
[95] Boyer-Neumann C, Brenot F, Wolf M, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995;73(4):735–6.
[96] Veyradier A., Nishikubo T., Humbert M.. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension Circulation 102 20 2000 2460 2462
[97] Friedman R., Mears J.G., Barst R.J.. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension Circulation 96 9 1997 2782 2784
[98] Girgis R.E., Champion H.C., Diette G.B.. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy Am J Respir Crit Care Med 172 3 2005 352 357
[99] Welsh C.H., Hassell K.L., Badesch D.B.. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension Chest 110 3 1996 710 717
[100] Loyd J.E., Atkinson J.B., Pietra G.G.. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension Am Rev Respir Dis 138 4 1988 952 957
[101] Frank H., Mlczoch J., Huber K.. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension Chest 112 3 1997 714 721
[102] Roman A., Rodes-Cabau J., Lara B.. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension Med Clin (Barc) 118 20 2002 761 766
[103] Storstein O., Efskind L., Muller C.. Primary pulmonary hypertension with emphasis on its etiology and treatment Acta Med Scand 179 2 1966 197 212
[104] Ansell J., Hirsh J., Poller L.. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 3 Suppl 2004 204S 233S
[105] Hales C.A., Kradin R.L., Brandstetter R.D.. Impairment of hypoxic pulmonary artery remodeling by heparin in mice Am Rev Respir Dis 128 4 1983 747 751
[106] Hassoun P.M., Thompson B.T., Hales C.A.. Partial reversal of hypoxic pulmonary hypertension by heparin Am Rev Respir Dis 145 1 1992 193 196
[107] Yu L., Quinn D.A., Garg H.G.. Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension Biochem Biophys Res Commun 345 4 2006 1565 1572
[108] Hassoun P.M., Thompson B.T., Steigman D.. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig Am Rev Respir Dis 139 3 1989 763 768
[109] Garg H.G., Hales C.A., Yu L.. Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative Carbohydr Res 341 15 2006 2607 2612
[110] Levine M.N.. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 3 Suppl 2004 287S 310S
[111] Robbins I.M.. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension Eur Respir J 27 3 2006 578 584
[112] Rubin L.J.. Pulmonary arterial hypertension Proc Am Thorac Soc 3 1 2006 111 115
[113] Geerts W.H.. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 3 Suppl 2004 338S 400S
[114] Dresdale D.T., Michtom R.J., Schultz M.. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance Bull N Y Acad Med 30 3 1954 195 207
[115] Christman B.W., McPherson C.D., Newman J.H.. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 2 1992 70 75
[116] Tuder R.M., Cool C.D., Geraci M.W.. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 6 1999 1925 1932
[117] Stewart D.J., Levy R.D., Cernacek P.. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114 6 1991 464 469
[118] Olivari M.T., Levine T.B., Weir E.K.. Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension Chest 86 1 1984 14 19
[119] Higenbottam T., Wheeldon D., Wells F.. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin) Lancet 1 8385 1984 1046 1047
[120] Groves B., Badesch D.B., Turkevich D.. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension and efficacy of treatment with calcium channel blockers and survival K. Weir Ion flux in pulmonary vascular control 1993 Plenum Press New York 317 330
[121] Sitbon O., Brenot F., Denjean A.. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin Am J Respir Crit Care Med 151 2 Pt 1 1995 384 389
[122] Sitbon O., Humbert M., Jagot J.L.. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension Eur Respir J 12 2 1998 265 270
[123] Pepke-Zaba J.H., Dinh-Xuan A.T., Stone D.. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension Lancet 338 8776 1991 1173 1174
[124] Ricciardi M.J., Knight B.P., Martinez F.J.. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine J Am Coll Cardiol 32 4 1998 1068 1073
[125] Schrader B.J., Inbar S., Kaufmann L.. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension J Am Coll Cardiol 19 5 1992 1060 1064
[126] Opitz C.F., Wensel R., Bettmann M.. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation Eur Heart J 24 4 2003 356 365
[127] Ogata M., Ohe M., Shirato K.. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension Jpn Circ J 57 1 1993 63 69
[128] Humbert M., Sitbon O., Chaouat A.. Pulmonary arterial hypertension in Fran results from a national registry Am J Respir Crit Care Med 173 9 2006 1023 1030
[129] Ziesche R., Petkov V., Wittmann K.. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension Heart 83 4 2000 406 409
[130] Preston I.R., Klinger J.R., Houtchens J.. Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome Chest 121 2 2002 656 659
[131] Zakliczynski M., Zebik T., Maruszewski M.. Usefulness of pulmonary hypertension reversibility test with sodium nitroprusside in stratification of early death risk after orthotopic heart transplantation Transplant Proc 37 2 2005 1346 1348
[132] Palmer S.M., Robinson L.J., Wang A.. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease Chest 113 1 1998 237 240